This article presents the current state of knowledge on hybrid therapies in orthopedics, combining biomaterials with biological therapies as a novel approach to treating bone fractures. Traditional methods, such as immobilization and internal fracture stabilization, are confronted with modern strategies that enrich the biological environment of the fracture site to promote osteogenesis. The article discusses in detail the mechanical and biological properties of biomaterials, including metals, ceramics and biodegradable polymers, and their role in osteosynthesis. The critical importance of stem cells, particularly mesenchymal stem cells (MSCs), and growth factors (BMPs and TGF-β), which promote bone regeneration through osteoblast differentiation and modulation of inflammatory processes, is highlighted. Hybrid therapies, in which scaffolds (scaffolds) serve as carriers for stem cells and growth factors, have shown high efficacy in accelerating healing and providing structural stability. Despite their many benefits, such as reduced recovery time and higher quality of regenerated bone tissue, hybrid therapies face significant challenges, including the risk of immune reactions, complexity of manufacturing processes and high cost, which limits their widespread clinical application. The article points to the need for further research into manufacturing technologies and cost reduction, which could make advanced therapies more accessible and more widely used in orthopedics.